Skip to main content
Erschienen in: International Cancer Conference Journal 1/2017

11.10.2016 | Case report

Exacerbation of gemcitabine-related pneumonia during radiotherapy for extrapulmonary lesion

verfasst von: Yukihiro Hama

Erschienen in: International Cancer Conference Journal | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Late-onset gemcitabine pulmonary toxicity is rare and association between pulmonary toxicity and radiotherapy to the extrapulmonary sites is controversial. Here, we report a case of acute exacerbated fatal interstitial pneumonia during radiotherapy to the extrapulmonary site. A 73-year-old woman with pelvic lymph node metastases from urothelial carcinoma underwent palliative radiotherapy after failure of gemcitabine-containing and gemcitabine-non-containing chemotherapy. Gemcitabine-containing chemotherapy had finished 13 months prior to the radiotherapy due to grade 3 pulmonary toxicity. During the course of radiotherapy to the pelvic lesion, she was complicated with fatal acute interstitial pneumonia even though the lung tissue was not irradiated. To the best of our knowledge, this is the first reported case of fatal gemcitabine-related pulmonary toxicity during radiotherapy for extrapulmonary lesion. Although the association between late-onset pulmonary toxicity and radiotherapy is controversial, caution should be paid to a patient with a history of gemcitabine-related pulmonary toxicity who will undergo radiotherapy even though the lung volume is not irradiated.
Literatur
1.
Zurück zum Zitat Arrieta O, Gallardo-Rincon D, Villarreal-Garza C et al (2009) High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol 4:845–852CrossRefPubMed Arrieta O, Gallardo-Rincon D, Villarreal-Garza C et al (2009) High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol 4:845–852CrossRefPubMed
3.
Zurück zum Zitat Maas KW, van der Lee I, Bolt K et al (2003) Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment. Lung Cancer 41:345–351CrossRefPubMed Maas KW, van der Lee I, Bolt K et al (2003) Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment. Lung Cancer 41:345–351CrossRefPubMed
4.
Zurück zum Zitat Dimopoulou I, Efstathiou E, Samakovli A et al (2004) A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann Oncol 15:1250–1255CrossRefPubMed Dimopoulou I, Efstathiou E, Samakovli A et al (2004) A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann Oncol 15:1250–1255CrossRefPubMed
5.
Zurück zum Zitat Belknap SM, Kuzel TM, Yarnold PR et al (2006) Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. Cancer 106:2051–2057CrossRefPubMed Belknap SM, Kuzel TM, Yarnold PR et al (2006) Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. Cancer 106:2051–2057CrossRefPubMed
6.
Zurück zum Zitat Plate JM, Plate AE, Shott S et al (2005) Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 54:915–925CrossRefPubMed Plate JM, Plate AE, Shott S et al (2005) Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 54:915–925CrossRefPubMed
7.
Zurück zum Zitat Nowak AK, Robinson BW, Lake RA (2002) Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 62:2353–2358PubMed Nowak AK, Robinson BW, Lake RA (2002) Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 62:2353–2358PubMed
8.
Zurück zum Zitat Bracci L, Schiavoni G, Sistigu A et al (2014) Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21:15–25CrossRefPubMed Bracci L, Schiavoni G, Sistigu A et al (2014) Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21:15–25CrossRefPubMed
Metadaten
Titel
Exacerbation of gemcitabine-related pneumonia during radiotherapy for extrapulmonary lesion
verfasst von
Yukihiro Hama
Publikationsdatum
11.10.2016
Verlag
Springer Japan
Erschienen in
International Cancer Conference Journal / Ausgabe 1/2017
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-016-0267-5

Weitere Artikel der Ausgabe 1/2017

International Cancer Conference Journal 1/2017 Zur Ausgabe

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.